Cost effectiveness of a pentavalent rotavirus vaccine in Oman

被引:7
作者
Al Awaidy, Salah Thabit [1 ,7 ]
Gebremeskel, Berhanu G. [2 ]
Al Obeidani, Idris [3 ]
Al Baqlani, Said [4 ]
Haddadin, Wisam [5 ]
O'Brien, Megan A. [6 ]
机构
[1] Minist Hlth, Off HE Hlth Affairs, Muscat, Oman
[2] Rutgers State Univ, Sch Publ Hlth, Piscataway, NJ USA
[3] Minist Hlth, DGHA, Dept Communicable Dis Surveillance & Control, Muscat, Oman
[4] Minist Hlth, DGHA, Cent Publ Hlth Lab, Muscat, Oman
[5] MSD EEMEA, Dubai, U Arab Emirates
[6] Merck & Co Inc, Global Hlth Outcomes, West Point, PA USA
[7] Minist Hlth, Off Undersecretary Hlth Affairs, Muscat 113, Oman
来源
BMC INFECTIOUS DISEASES | 2014年 / 14卷
关键词
Rotavirus; Vaccine; Cost effectiveness; Oman; Markov model; ACUTE GASTROENTERITIS; CHILDREN YOUNGER; INFECTION; MORTALITY; DISEASE; IMPACT; POPULATION; PROTECTION; PARENTS; BURDEN;
D O I
10.1186/1471-2334-14-334
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Rotavirus gastroenteritis (RGE) is the leading cause of diarrhea in young children in Oman, incurring substantial healthcare and economic burden. We propose to formally assess the potential cost effectiveness of implementing universal vaccination with a pentavalent rotavirus vaccine (RV5) on reducing the health care burden and costs associated with rotavirus gastroenteritis (RGE) in Oman Methods: A Markov model was used to compare two birth cohorts, including children who were administered the RV5 vaccination versus those who were not, in a hypothetical group of 65,500 children followed for their first 5 years of life in Oman. The efficacy of the vaccine in reducing RGE-related hospitalizations, emergency department (ED) and office visits, and days of parental work loss for children receiving the vaccine was based on the results of the Rotavirus Efficacy and Safety Trial (REST). The outcome of interest was cost per quality-adjusted life year (QALY) gained from health care system and societal perspectives. Results: A universal RV5 vaccination program is projected to reduce, hospitalizations, ED visits, outpatient visits and parental work days lost due to rotavirus infections by 89%, 80%, 67% and 74%, respectively. In the absence of RV5 vaccination, RGE-related societal costs are projected to be 2,023,038 Omani Rial (OMR) (5,259,899 United States dollars [USD]), including 1,338,977 OMR (3,481,340 USD) in direct medical costs. However, with the introduction of RV5, direct medical costs are projected to be 216,646 OMR (563,280 USD). Costs per QALY saved would be 1,140 OMR (2,964 USD) from the health care payer perspective. An RV5 vaccination program would be considered cost saving, from the societal perspective. Conclusions: Universal RV5 vaccination in Oman is likely to significantly reduce the health care burden and costs associated with rotavirus gastroenteritis and may be cost-effective from the payer perspective and cost saving from the societal perspective.
引用
收藏
页数:9
相关论文
共 29 条
  • [1] Considerations for Introduction of a Rotavirus Vaccine in Oman: Rotavirus Disease and Economic Burden
    Al Awaidy, S. A.
    Bawikar, S.
    Al Busaidy, S.
    Baqiani, S.
    Al Abedani, I.
    Varghese, R.
    Abdoan, H. S.
    Al Abdoon, H.
    Bhatnagar, S.
    Al Hasini, K. S.
    Mohan, P.
    Shah, S.
    Elamir, E.
    Klena, J.
    Ahmed, S. F.
    Teleb, N.
    Parashar, U.
    Patel, M. M.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2009, 200 : S248 - S253
  • [2] [Anonymous], 2007, TABLES COSTS PRICES
  • [3] Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030
    Atherly, Deborah E.
    Lewis, Kristen D. C.
    Tate, Jacqueline
    Parashar, Umesh D.
    Rheingans, Richard D.
    [J]. VACCINE, 2012, 30 : A7 - A14
  • [4] Effectiveness of Pentavalent Rotavirus Vaccine in a Large Urban Population in the United States
    Boom, Julie A.
    Tate, Jacqueline E.
    Sahni, Leila C.
    Rench, Marcia A.
    Hull, Jennifer J.
    Gentsch, Jon R.
    Patel, Manish M.
    Baker, Carol J.
    Parashar, Umesh D.
    [J]. PEDIATRICS, 2010, 125 (02) : E199 - E207
  • [5] Rotavirus Vaccines in Belgium Policy and Impact
    Braeckman, Tessa
    Van Herck, Koen
    Raes, Marc
    Vergison, Anne
    Sabbe, Martine
    Van Damme, Pierre
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (01) : S21 - S24
  • [6] An introduction to Markov modelling for economic evaluation
    Briggs, A
    Sculpher, M
    [J]. PHARMACOECONOMICS, 1998, 13 (04) : 397 - 409
  • [7] HEALTH-RELATED QUALITY OF LIFE LOST TO ROTAVIRUS-ASSOCIATED GASTROENTERITIS IN CHILDREN AND THEIR PARENTS A CANADIAN PROSPECTIVE STUDY
    Brisson, Marc
    Senecal, Martin
    Drolet, Melanie
    Mansi, James A.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (01) : 73 - 75
  • [8] Reduction in Rotavirus-associated Acute Gastroenteritis Following Introduction of Rotavirus Vaccine Into Australia's National Childhood Vaccine Schedule
    Buttery, Jim P.
    Lambert, Stephen B.
    Grimwood, Keith
    Nissen, Michael D.
    Field, Emma J.
    Macartney, Kristine K.
    Akikusa, Jonathan D.
    Kelly, Julian J.
    Kirkwood, Carl D.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (01) : S25 - S29
  • [9] Clio-Infra Project, 2013, GDP PER CAP
  • [10] ESTIMATES OF MORBIDITY AND MORTALITY-RATES FOR DIARRHEAL DISEASES IN AMERICAN CHILDREN
    GLASS, RI
    LEW, JF
    GANGAROSA, RE
    LEBARON, CW
    HO, MS
    [J]. JOURNAL OF PEDIATRICS, 1991, 118 (04) : S27 - S33